Uveal melanoma is the most common primary intraocular malignancy in adults. Localized tumors are often curable by local therapy, but about 50% of patients develop a relapse with metastatic disease, particularly in the liver. Mortality rate after detected liver metastases remains high, while systemic therapies usually provide marginal benefit. Melanomas are hypervascular tumors, and agents with antiangiogenic activities have been studied as palliative treatment. Interferon-alpha-2b (IFN-α2b) has antiangiogenic activity when administered at low doses. We describe a patient who has received low-dose subcutaneous IFN-α2b (0.9 MIU, tid) continuously for years and gained stabilization of lung and liver metastases, which had previously progressed during earlier systemic therapies.

This content is only available via PDF.
Open Access License / Drug Dosage / Disclaimer
Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.